The short version of anti-doping fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-07. Anything still debated is marked as such rather than presented as settled.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Research-use-only status in many markets |
| WADA status | Prohibited in sport | Generally listed as a non-approved substance |
| Detection technique | LC-MS/MS | Common for urine and blood analysis |
| Common alias | Stenabolic | Informal market nickname, not a pharmacopoeial name |
| Purity check | HPLC or LC-UV | Independent certificate of analysis is typical |
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
Wilson pleaded no contest to the assault and was sentenced in 2010 to two years in prison. In 2017, when The Wolf of Wall Street producer Red Granite Pictures was involved in the 1Malaysia Development Berhad scandal, DiCaprio turned over the gifts he received from business associates at the production company, including from fugitive businessman Jho Low, to the US government. These included a Best Actor Oscar trophy won by Marlon Brando, a $3.2 million Pablo Picasso painting, and a $9 million Jean-Michel Basquiat collage.
=== Electronic cross-matching === Electronic cross-matching is a computer-assisted analysis using data, from the donor unit (where a donor's blood is tested prior to donation) and testing done on blood samples from the intended recipient. This includes ABO/Rh typing of the unit and of the recipient, and an antibody screen of the recipient. Electronic cross-matching can only be used if a patient has a negative antibody screen, which means that they do not have any active red blood cell atypical antibodies, or they are below the detectable level of current testing methods. If all of the data entered is compatible, the computer will print a compatibility label stating that the unit is safe to transfuse.
Controlled priming and PCR amplification: Adapter-Linker PCR WGA Random priming and PCR amplification: DOP-PCR, MALBAC Random priming and isothermal amplification: MDA The Adapter-Linker PCR WGA is reported in many comparative studies to be the best-performing technique for diploid single-cell mutation analysis, thanks to its very low Allelic Dropout effect, and for copy number variation profiling due to its low noise, both with aCGH and with NGS low Pass Sequencing. This method is only applicable to human cells, both fixed and unfixed. One widely adopted WGA technique is called degenerate oligonucleotide–primed polymerase chain reaction (DOP-PCR). This method uses the well established DNA amplification method PCR to try and amplify the entire genome using a large set of primers. Although simple, this method has been shown to have very low genome coverage. An improvement on DOP-PCR is Multiple displacement amplification (MDA), which uses random primers and a high fidelity enzyme, usually Φ29 DNA polymerase, to accomplish the amplification of larger fragments and greater genome coverage than DOP-PCR. Despite these improvements MDA still has a sequence-dependent bias (certain parts of the genome are amplified more than others because of their sequence, causing some parts to be overrepresented in the resulting genomic dataset). The method shown to largely avoid the biases seen in DOP-PCR and MDA is Multiple Annealing and Looping–Based Amplification Cycles (MALBAC). Bias in this system is reduced by only copying off the original DNA strand instead of making copies of copies.
Ergometrine, which is a minor constituent representing up to 8% of total alkaloids, is known to produce psychedelic effects only in higher amounts (2–10 mg) than those in typical doses of morning glory seeds and hence is thought to not contribute to the effects of the seeds either. Moreover, ergometrine is present in Ipomoea tricolor and Argyreia nervosa but not in Ipomoea corymbosa. Isoergine being responsible for the hallucinogenic effects of morning glory seeds is also supported by animal studies. According to Alexander Shulgin in his 1997 book TiHKAL (Tryptamines I Have Known and Loved) however, both ergine and isoergine are "probably correctly dismissed" as not contributing to the effects of morning glory seeds. The poorly-stable lysergic acid hydroxyethylamides (LSHs) might alternatively be involved in the psychedelic effects of morning glory seeds per Shulgin.
Sources: en.wikipedia.org
== Atrial fibrillation == Pulmonary vein isolation has been the mainstay of atrial fibrillation reduction, but in many cases there are other sources of arrhythmia, including the LoM. Use of ethanol through the VoM has been shown to be an effective way to reduce atrial fibrillation.
== External links == Clinical trial number NCT02229851 for "Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin FlexPro (Somatropin) in Adults With Growth Hormone Deficiency. (REAL 1)" at ClinicalTrials.gov
=== Recurring === Eme Ikwuakor as Elijah, an attorney at Jacobson Moore who was in a romantic relationship with Olympia Beau Bridges as Howard "Senior" Markston, a managing partner at Jacobson Moore, father of Julian, and soon-to-be ex-father-in-law of Olympia. He guardedly supports Olympia's career and efforts to develop a new revenue stream for the firm, telling her how he believes being father-in-law is a forever role. Patricia Belcher as Mrs. B, an administrative manager at Jacobson Moore. It is later revealed her full name is Emmalyn Belvin. Yael Grobglas as Shae Banfield, a jury consultant at Jacobson Moore Piper Curda as Kira, a woman who works at the information technology (IT) department at Jacobson Moore who begins a relationship with Sarah Marnee Carpenter as Ellie Kingston, Matty and Edwin's deceased daughter and Alfie's mother, who appears in flashbacks Andrea Londo as Simone, a recently hired junior associate at Jacobson Moore who attended the same law school as Sarah Niko Nicotera as Joseph "Joey" Danza, Alfie's father who is a drug addict Justina Machado as Eva (season 2), Senior's fourth ex-wife who is also a lawyer and member of the executive committee at Jacobson Moore James Lesure as Lester "The Wolf" Logan (season 2) Justin Cornwell as Mr. Hodges (season 2), Olympia's love interest who is also a lawyer Sarah Wright Olsen as Gwen (season 2), a productivity consultant evaluating Jacobson Moore Henry Haber as Hunter (season 2), an eager new associate on Olympia's team
Sources: en.wikipedia.org
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.
Anti-doping laboratories typically use LC-MS/MS to detect SR9009 or its metabolites in urine or blood. The exact assay depends on the laboratory and the testing program. Detection can be challenging because the compound may be rapidly metabolized and present at low levels.
Stenabolic is an informal nickname used in online fitness and research-chemical markets, not an official drug name. It likely references reported effects on endurance in rodent studies. The nickname does not imply approval or proven human benefit.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.